Inactive Instrument

Highlights Provention Bio, Inc.

Equities

PRVB

US74374N1028

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sanofi Completes Provention Bio Acquisition	23-04-27	MT
Sanofi: acquisition of Provention Bio finalized	23-04-27	CF
Provention Bio : Termination of Material Agreement - Form 8-K	23-04-27	PU
PROVENTION BIO, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-04-27	AQ
Sanofi Closes $3 Billion Acquisition of Provention Bio	23-04-27	MT
Sanofi completed the acquisition of 97.1% stake in Provention Bio, Inc..	23-04-26	CI
Sanofi Secures US Antitrust Clearance for $2.9 Billion Provention Bio Takeover	23-04-26	MT
Sanofi wins US drug control from AstraZeneca in Sobi deal	23-04-11	AN
Sanofi Extends Offer Period for Provention Bio Takeover Amid US Regulatory Review	23-04-11	MT
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
Fed's US Bank Rescue Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Monday	23-03-13	MT
Sanofi to Acquire Provention Bio in $2.9 Billion Deal	23-03-13	MT
Sanofi to Boost General Medicines Portfolio Via $3 Billion Takeover of US-based Provention Bio	23-03-13	MT
Sanofi to Acquire Provention Bio for Around $2.9 Billion	23-03-13	DJ
Sanofi to Buy Autoimmune Disease-focused Provention Bio for $2.9 Billion	23-03-13	MT
Sanofi entered into an agreement to acquire 97.1% stake in Provention Bio, Inc. for $2.3 billion.	23-03-12	CI
Provention Bio, Inc. Announces U.S. Commercial Launch of Tzield	23-02-02	CI
Provention Bio diabetes drug to cost $13,850 a vial	22-11-18	RE
U.S. FDA greenlights Provention Bio's diabetes drug	22-11-17	RE
Provention Bio, Inc. Announces United States Food and Drug Administration Approves the Biologics License Application for TZIELD	22-11-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Provention Bio, Inc.

Equities

PRVB

US74374N1028

Highlights

Filters